Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy-induced peripheral neuropathy.

Constance Visovsky1

  • 1Frances Payne Bolton School of Nursing, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106, USA. cxv6@po.cwru.edu

Cancer Investigation
|August 7, 2003
PubMed
Summary

Chemotherapy can prolong cancer survival but often causes peripheral neuropathy, a sensory side effect. This condition is dose-related, cumulative, and requires attention as cancer survivorship increases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality of Life in Cancer Care and the Importance of Physical Activity, Sleep, and Social Determinants of Health.

Clinical journal of oncology nursing·2026
Same author

Qualitative Evaluation of Financial Toxicity and Supportive Care Needs of Women Living With Metastatic Breast Cancer.

Nursing research·2025
Same author

Risk Factors and Predictors for Persistent Dyspnea Post-COVID-19: A Systematic Review.

Clinical nursing research·2025
Same author

Resettlement needs of refugee women in the United States: An American Academy of Nursing consensus paper.

Nursing outlook·2024
Same author

Fall Risk Associated with Taxanes: Focus on Chemotherapy-Induced Peripheral Neuropathy.

Seminars in oncology nursing·2024
Same author

Process evaluation protocol plan for a home-based physical activity intervention versus educational intervention for persistent taxane-induced peripheral neuropathy (B-HAPI study): a randomized controlled trial.

BMC cancer·2024

Area of Science:

  • Oncology
  • Neurology
  • Public Health

Background:

  • Cancer survivorship is increasing due to novel treatments.
  • Chemotherapeutic agents are crucial for cancer cure, control, and palliation.
  • Chemotherapy use is associated with significant adverse side effects.

Purpose of the Study:

  • To highlight peripheral neuropathy as a critical consequence of cancer therapy.
  • To underscore the growing importance of managing long-term functional deficits from cancer treatments.

Main Methods:

  • Review of clinical evidence linking neurotoxic agents to peripheral neuropathy.
  • Identification of specific drug categories implicated in chemotherapy-induced peripheral neuropathy (CIPN).

Main Results:

  • Chemotherapy-induced peripheral neuropathy (CIPN) is a common neurotoxic side effect.
  • CIPN is sensory, dose-dependent, cumulative, and typically delayed.
  • Plant alkaloids, interferons, antimitotics, taxanes, and platinum compounds are key culprits.

Conclusions:

  • Peripheral neuropathy is an emerging and significant consequence of modern cancer therapy.
  • Increased cancer survivorship necessitates addressing long-term functional deficits, including CIPN.
  • Management of CIPN is crucial for improving quality of life in cancer survivors.

Related Experiment Videos